Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05445310

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer: a Prospective Single-arm Study

Sponsor: Peking Union Medical College Hospital

Conditions Non-small Cell Lung Cancer

Interventions Furmonertinib

Updated 4 times since 2022 Last updated: Feb 14, 2023 Started: Aug 6, 2022 Primary completion: Jul 1, 2026 Completion: Jul 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Peking Union Medical College Hospital and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking Union Medical College Hospital

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China